Three new Directors appointed, page-79

QUOTE="Southoz, post: 15098381, member: 55593"]Your one liners (post before) are getting better by the day Playez.

But to Henriette; the top 20 of the POH share register of POH is dominated by several large nominee holders.

My understanding is that it is virtually impossible for anyone (even the company) to penetrate nominee accounts to uncover the identities of the actual beneficiary owners.

There are a few very specialised companies in Australia that will do this detective work – but it is costly, difficult and time consuming.

Other than Gray I have assumed most of the nominee holders are overseas based – most likely US. And no you won’t see any substantial holder notices.

A significant share price drop in the absence of any terrible fundamental news, and couple of new Director faces popping up does point you to some sort of Board shenanigans. A tussle for control.

This does all look like to be coming to a head. A decade and $100m plus in losses is a fair suck of the sauce bottle. People don’t like losing millions of dollars, they lose their patience and a view forms that it is time for a new story or at least new story tellers.

Lifestyle changes are very difficult for everyone; noses get out joint all round. I think you were right about one thing … retail investors get caught in the cross-fire.

The view that shares are being transferred from weak to strong hands … completely fanciful. But its my job on HC to always construct the most gloomiest scenarios possible. I fail regularly … often things turn out to be much worse. But sometimes the best buying is when things look at their worst; so its all very tricky.

All the best Southoz[/QUOTE]

Well said...

and...down to 2.8cents..

If the tech actually worked for pain we would be in phase 3 systemic oxycodone by now..not testing a whole bunch of non oxycodone opiates and topical local opiate therapy for neuropathic pain (which by the way, does not have a great medical or scientific basis). Opiates don't work well for neuropathic pain, I'm not sure what's gotten into them, they should make the systemic oxycodone patch work. The fact they are not pursuing that now suggests the phase 2 trial from 2008 failed.

I guess throwing tpm into animal feed has perhaps bought a bit of time...but despite this the sp continues to drop.